Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 22:13:956397.
doi: 10.3389/fphar.2022.956397. eCollection 2022.

Individualized medication based on pharmacogenomics and treatment progress in children with IgAV nephritis

Xuerong Yang  1   2 , Qi Li  1   2 , Yuanyuan He  1   2 , Yulian Zhu  3 , Rou Yang  1   2 , Xiaoshi Zhu  4 , Xi Zheng  1   2 , Wei Xiong  5 , Yong Yang  1   2
Affiliations
Review

Individualized medication based on pharmacogenomics and treatment progress in children with IgAV nephritis

Xuerong Yang et al. Front Pharmacol. .

Abstract

Immunoglobulin A vasculitis (IgAV) nephritis, also known as Henoch-Schönlein purpura nephritis (HSPN), is a condition in which small blood vessel inflammation and perivascular IgA deposition in the kidney caused by neutrophil activation, which more often leads to chronic kidney disease and accounts for 1%-2% of children with end-stage renal disease (ESRD). The treatment principles recommended by the current management guidelines include general drug treatment, support measures and prevention of sequelae, among which the therapeutic drugs include corticosteroids, immunosuppressive agents and angiotensin system inhibitors. However, the concentration range of immunosuppressive therapy is narrow and the individualized difference is large, and the use of corticosteroids does not seem to improve the persistent nephropathy and prognosis of children with IgAV. Therefore, individualized maintenance treatment of the disease and stable renal prognosis are still difficult problems. Genetic information helps to predict drug response in advance. It has been proved that most gene polymorphisms of cytochrome oxidase P450 and drug transporter can affect drug efficacy and adverse reactions (ADR). Drug therapy based on genetics and pharmacogenomics is beneficial to providing safer and more effective treatment for children. Based on the pathogenesis of IgAV, this paper summarizes the current therapeutic drugs, explores potential therapeutic drugs, and focuses on the therapeutic significance of corticosteroids and immunosuppressants in children with IgAV nephritis at the level of pharmacogenomics. In addition, the individualized application of corticosteroids and immunosuppressants in children with different genotypes was analyzed, in order to provide a more comprehensive reference for the individualized treatment of IgAV nephritis in children.

Keywords: Henoch-Schönlein purpura nephritis; IgA vasculitis nephritis; gene polymorphism; immunosuppressants; paediatric; personalized medicine; pharmacogenomics; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Abu-Zaid M. H., Salah S., Lotfy H. M., El Gaafary M., Abdulhady H., Tabra S. A. A., et al. (2021). Consensus evidence-based recommendations for treat-to-target management of immunoglobulin a vasculitis. Ther. Adv. Musculoskelet. Dis. 13, 1759720X211059610. 10.1177/1759720x211059610 - DOI - PMC - PubMed
    1. Adami G., Saag K. G. (2019). Glucocorticoid-induced osteoporosis: 2019 concise clinical review. Osteoporos. Int. 30 (6), 1145–1156. 10.1007/s00198-019-04906-x - DOI - PubMed
    1. Afsar N. A., Ufer M., Haenisch S., Remmler C., Mateen A., Usman A., et al. (2012). Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients. Eur. J. Clin. Pharmacol. 68 (4), 389–395. 10.1007/s00228-011-1134-0 - DOI - PubMed
    1. Allison A. C., Eugui E. M. (2000). Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47 (2-3), 85–118. 10.1016/s0162-3109(00)00188-0 - DOI - PubMed
    1. Appell M. L., Berg J., Duley J., Evans W. E., Kennedy M. A., Lennard L., et al. (2013). Nomenclature for alleles of the thiopurine methyltransferase gene. Pharmacogenet Genomics 23 (4), 242–248. 10.1097/FPC.0b013e32835f1cc0 - DOI - PMC - PubMed